Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (AVIR) is a clinical-stage biopharmaceutical company pioneering oral antiviral therapies for severe viral diseases. This page provides investors and healthcare professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Key resources include: Press releases detailing study results, partnership announcements with research institutions, and financial disclosures. Track updates on COVID-19 therapeutic candidates, hepatitis C treatments, and emerging programs targeting RNA viruses.
All content is sourced directly from company filings and official communications to ensure accuracy. Visitors can expect detailed coverage of Phase 2/3 trial outcomes, FDA interactions, and strategic initiatives advancing antiviral drug development.
Bookmark this page for consolidated access to AVIR's latest scientific advancements and business updates. Check regularly for new developments from Atea's nucleos(t)ide prodrug platform and pipeline expansion efforts.
Atea Pharmaceuticals (Nasdaq: AVIR) has received Fast Track designation from the FDA for its oral antiviral drug candidate, bemnifosbuvir, intended for treating COVID-19. This designation aims to expedite the drug's development due to significant unmet medical needs in vulnerable patient populations, including high-risk outpatients aged 18 and older regardless of vaccination status. Currently undergoing the Phase 3 SUNRISE-3 trial, bemnifosbuvir is being assessed in over 1,500 participants across approximately 300 sites globally. The trial will evaluate the drug's effectiveness against severe COVID-19 outcomes. Fast Track status will enable more frequent communications with the FDA and a potential rolling review for the New Drug Application.
Atea Pharmaceuticals presented significant findings from the MORNINGSKY Phase 3 trial of bemnifosbuvir for treating mild to moderate COVID-19. The study revealed a 71% reduction in hospitalization risk for patients treated with bemnifosbuvir compared to placebo. Notably, patients over 40 years showed an 82% reduction in hospitalization risk. Despite not meeting its primary endpoint of symptom alleviation, bemnifosbuvir demonstrated lower rates of hospitalization and treatment discontinuations due to adverse events compared to placebo. The investigational drug is now part of a global Phase 3 trial, SUNRISE-3. Atea also shared data on AT-752, an antiviral for dengue, which was well tolerated in early studies. These developments could enhance Atea's position in the antiviral market.
Atea Pharmaceuticals (Nasdaq: AVIR) announced promising Phase 1 data on bemnifosbuvir, its oral antiviral candidate for COVID-19 and hepatitis C (HCV), at the ICAR 2023 conference. Key findings reveal a favorable absorption and metabolism profile for bemnifosbuvir, demonstrating low risk for drug-drug interactions, effective inhibition against all SARS-CoV-2 variants, and potential synergistic effects when combined with ruzasvir against HCV. These results underscore bemnifosbuvir's high barrier to resistance and safety for vulnerable patients. The drug is currently undergoing a Phase 3 trial (SUNRISE-3) for COVID-19 and is in Phase 2 development for HCV treatment.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced six upcoming presentations at the 36th International Conference on Antiviral Research (ICAR) from March 13-17, 2023, in Lyon, France. Key presentations include:
- The synergistic effects of Bemnifosbuvir and Ruzasvir in treating HCV.
- Low risk of drug-drug interactions for Bemnifosbuvir.
- Pharmacokinetics of [14C]-Bemnifosbuvir.
- Bemnifosbuvir as a potent inhibitor of SARS-CoV-2 variants.
- AT-752 targeting Dengue virus replication.
- Cellular enzymes in the activation pathway of Bemnifosbuvir.
Atea focuses on developing oral therapies for serious viral infections and aims to expand its antiviral pipeline.
Atea Pharmaceuticals (Nasdaq: AVIR) reported its fourth-quarter and full-year 2022 financial results, showing a net loss of $34.4 million and a decline in cash and equivalents to $646.7 million. The company continues enrollment in its Phase 3 SUNRISE-3 trial for bemnifosbuvir, targeting COVID-19 treatment in high-risk patients, with an interim analysis expected in the second half of 2023. Atea has also deprioritized its dengue program to focus on COVID-19 and HCV, with a Phase 2 trial of bemnifosbuvir and ruzasvir for hepatitis C anticipated to start in Q2 2023. The overall research and development expenses decreased significantly due to the cessation of its collaboration with Roche.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced promising results from three Phase 1 studies of bemnifosbuvir presented at the CROI conference (Feb 19-22, 2023). The data indicates that bemnifosbuvir has a favorable drug-drug interaction profile, requiring no dosage adjustments when co-administered with CYP3A substrates and other commonly prescribed medications for patients at risk of severe COVID-19. This investigational antiviral is currently being evaluated in the Phase 3 SUNRISE-3 trial targeting high-risk non-hospitalized COVID-19 patients. The findings highlight bemnifosbuvir's potential to safely enhance treatment options for vulnerable populations.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced a live conference call scheduled for February 28, 2023, at 4:30 p.m. ET. The call will disclose financial results for the fourth quarter and full year ended December 31, 2022, alongside a business update. Atea focuses on developing oral therapies for serious viral diseases, including COVID-19 and hepatitis C, utilizing its proprietary nucleos(t)ide prodrug platform. The event will be accessible via registration, with a live webcast available on the Atea website. Archived content will be accessible for 90 days post-event.
BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced two poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) taking place from February 19-22, 2023, in Seattle. The posters include:
- Poster 512: No Dose Adjustments for CYP3A4 Substrates with Bemnifosbuvir
- Poster 513: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated Transport
Atea focuses on developing oral therapies for severe viral diseases and utilizes a proprietary nucleos(t)ide prodrug platform to create candidates targeting ssRNA viruses like COVID-19, dengue, and hepatitis C.
BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that its CEO, Jean-Pierre Sommadossi, will present a business update during a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:00 p.m. ET. A live webcast of the event will be accessible here and will remain available for 90 days after the event.
Atea specializes in developing oral therapies for severe viral diseases, focusing on antiviral treatments for COVID-19, dengue, and HCV.
Atea Pharmaceuticals (Nasdaq: AVIR) provided a clinical update, highlighting progress in its pipeline for 2023. The SUNRISE-3 Phase 3 trial for bemnifosbuvir, targeting high-risk, non-hospitalized COVID-19 patients, continues with interim analysis expected in 2H23. The company anticipates proof-of-concept results for AT-752 for dengue in 1Q23, and initiation of a Phase 2 study of bemnifosbuvir and ruzasvir for Hepatitis C in 2Q23, with data expected in 4Q23. Atea boasts a strong balance sheet to support these initiatives through 2025.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
